Vitality Watch

Dossier pubmed trial early 01-oct-2026
Small or early-phase human trial or pilot study

Senolytics dasatinib and quercetin in metabolic dysfunction-associated steatohepatitis: a proof-of-principle randomized, controlled trial.

Key claim: Intermittent dasatinib plus quercetin senolytic therapy improved liver fibrosis by ≥1 stage without MASH worsening in 47% of participants versus 7% on placebo, and resolved MASH more often, in a phase-2 randomized trial of fibrotic MASH.

Abstract

Cellular senescence plays an important role in hepatic inflammation and fibrosis. However, whether senescence represents a potential therapeutic target in humans with metabolic dysfunction-associated steatohepatitis (MASH) remains unexplored. Here we report the results of a phase-2, double-blind, randomized, placebo-controlled trial of intermittent senolytic therapy with dasatinib plus quercetin (D + Q) in participants with fibrotic MASH. Thirty-one participants (median age 56 years; 76% male; 58% with type 2 diabetes) were randomized (1:1) to receive D + Q (dasatinib 100 mg per day plus quercetin 1,000 mg per day) or placebo for three consecutive days per week over 3 weeks, repeated across three 7-week cycles. The primary endpoint, ≥1 stage fibrosis improvement without MASH worsening on paired liver biopsies, is achieved in 47% of D + Q-treated participants versus 7% with placebo (P = 0.02). MASH resolution occurs more frequently with D + Q than placebo (53% versus 7%; P = 0.02), with a greater reduction in NAFLD Activity Score (-1.43 ± 1.22 versus -0.39 ± 0.77; P = 0.012). Single-nucleus RNA sequencing demonstrates decreased senescence and fibrotic gene signatures and reduced fibrogenic cell populations in the D + Q group. Although adverse events are more frequent in the D + Q group (82% versus 43%), these are all self-limiting. Overall, this proof-of-principle trial supports the need for future trials of senolytic therapy in fibrotic MASH. ClinicalTrials.gov identifier: NCT05506488 .

Why this matters

Until now, the dasatinib+quercetin senolytic case rested almost entirely on mouse models and uncontrolled small human pilots; this is the first randomized, placebo-controlled trial to show a hard tissue endpoint (paired-biopsy fibrosis regression) in a defined disease population, with molecular confirmation that senescent and fibrogenic cell populations declined. It moves D+Q from a preclinical/biohack narrative toward a drug-development track in MASH, while leaving open whether the biopsy signal translates to clinical outcomes, generalizes beyond MASH, or scales safely with repeated intermittent dosing.

Source

Link

Briefing card

Senolytics dasatinib and quercetin in metabolic dysfunction-associated steatohepatitis: a proof-of-principle randomized, controlled trial.
Stage: trial early · pubmed · 01-oct-2026

If you have fibrotic MASH, this early trial found that intermittent dasatinib plus quercetin improved liver fibrosis by at least one stage in roughly 47% of participants versus 7% on placebo.

Intermittent dasatinib plus quercetin senolytic therapy improved liver fibrosis by ≥1 stage without MASH worsening in 47% of participants versus 7% on placebo, and resolved MASH more often, in a phase-2 randomized trial of fibrotic MASH.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1038/s42255-026-01643-4

build build 880 · 2bcef25 · 2026-11-18